Lifecore Biomedical, Inc.: financial statements

LFCRNASDAQHealthcare · Pharmaceutical Preparations

Price

$6.39

November 20, 2026Market cap $239M

What Ploutos Investor adds for Lifecore Biomedical

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 16 fiscal years, from FY2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

FY2023–FY2025 fiscal years

Click a line to see it on the chart.

Revenue

LineFY2023FY2024FY2025Average a year
Revenue $103M$128M$129M
Cost of revenue $75M$86M$89M
Gross profit $28M$42M$40M
Operating income -$22M-$8.8M-$17M
Net income -$100M$12M-$39M
Earnings per share -$3.32$0.33-$1.27
Earnings per share, basic -$3.32$0.39-$1.27
Margins
Gross margin 27.1%32.6%31.3%
Operating margin -21.1%-6.9%-13.4%
Net margin -96.4%9.4%-30.0%

Financial statements

LFCR's revenue, profits and cash flows from FY2010 to FY2022, 13 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • FY2020: Lifecore $86M, Curation Foods $74M
SegmentFY2020Share FY2020
Lifecore$86M54%
Curation Foods$74M46%

By segment

LFCR's revenue by segment from FY2014 to FY2019, 6 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Left out: FY2021, FY2022. In those filings two breakdowns were tagged at once (product lines beside regions), so the lines add up to well over the company's revenue.

From the XBRL of 13 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$1.9M Due within 2 years$7.4M Leases-0.1% Effective tax rate

The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

When the debt falls due

Dec 31, 2025

Due within 2 years

$1.9M

Total falling due

$196M

Total in the ladder $196M, from the annual report dated December 31, 2025. Principal of loans and bonds, without leases and interest. The filing

  • 2026: $954.0K
  • 2027: $986.0K
  • 2028: $1.0M
  • 2029: $185M
  • 2030: $1.1M
  • 2031 on: $6.6M

The ladder at each year end

Year1 yr2 yrs3 yrs4 yrs5 yrsLater
2025$954.0K$986.0K$1.0M$185M$1.1M$6.6M
FY2025$3.4M$967.0K$1.0M$175M$1.1M$7.3M
FY2024$773.0K$773.0K$773.0K$773.0K$773.0K$161M

The ladder at each year end

When LFCR's debt fell due, as each annual report set it out, from FY2013 to FY2022, 10 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Leases

Dec 31, 2025

Operating leases

$1.5M

Finance leases

$5.9M

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Operating lease payments by year

Goodwill by segment

Dec 31, 2025

Total goodwill

$14M

The company does not state its goodwill by segment, at December 31, 2025. The filing

Goodwill by year

Goodwill by year

LFCR's goodwill from FY2012 to FY2023, 12 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the statutory to the effective tax rate, FY2025

May 25, 2025

Statutory rate

21.0%

Effective rate

-0.1%

-21.1 pts

The company paid -0.1% in tax on its profit, 21.1 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Impairments

+1.9 pts

Tax credits

+1.4 pts

State and local taxes

+0.5 pts

Change in valuation allowance

-22.1 pts

Share-based compensation

-2.1 pts

Prior-year adjustments

-0.6 pts

Other

-0.3 pts

Effective rate

-0.1%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Effective tax rate by year

In a year of a loss or of very small profits the rate comes out negative or very large and says little. Those years are in grey.

Effective tax rate by year

The tax rate LFCR paid on its profit, from FY2011 to FY2022, 12 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

$51M ahead of the shares21% of market value

$51M of other claims rank ahead of the shares, about 21% of the market value.

Ahead of the shares

at Sep 30, 2026
$51M

From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 20, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Taxes: deferred and paid

The deferred part was -276.7% of the tax charge in the year to May 25, 2025. The rows show the last 3 years.

Cash taxes paid were 28.4% of the current tax charge in the year to May 25, 2025.

  • Cash taxes paid against the current charge are lower than at nine in ten S&P 500 companies.
Deferred share, year to May 25, 2025-$119.0K of $43.0K
-276.7%
Deferred share, year to May 26, 2024$156.0K of $183.0K
85.3%
Deferred share, year to May 28, 2023$254.0K of $308.0K
82.5%
$46.0K paid, $162.0K current
28.4%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.

Receivables and inventory against sales are not shown: a figure it needs is missing from the company's structured filings.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Lifecore Biomedical's filings show?

These are Lifecore Biomedical's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about LFCR's financials

Didn't find what you were looking for?

Ask us
How much revenue did LFCR have in FY2025?

Lifecore Biomedical had revenue of $129M and net income of -$39M in fiscal FY2025, a net margin of -30.0%.

How much debt does LFCR have?

On May 25, 2025 Lifecore Biomedical had total assets of $239M, debt of $134M and shareholders' equity of $1.3M.

How much free cash flow does LFCR have?

In fiscal FY2025 Lifecore Biomedical had cash from operations of -$206.0K and spent $13M on capital expenditure, leaving -$14M of free cash flow.

Where are the figures from?

From Lifecore Biomedical, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.